Chinese COVID vaccine trial shows strong immune response
NCT ID NCT04649021
First seen Mar 31, 2026 · Last updated Apr 26, 2026 · Updated 5 times
Summary
This study tested the safety and immune response of the BNT162b2 mRNA COVID-19 vaccine in 960 healthy Chinese adults aged 18 to 85. Participants received two shots, 21 days apart, of either the vaccine or a placebo. The main goal was to see if the vaccine triggered a strong antibody response against the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing, 210009, China
Conditions
Explore the condition pages connected to this study.